![](https://cdn.sanity.io/images/0vv8moc6/onclive/9680a68c0a2cb2d0d6e5e45a65705dcb4a15681f-200x200.jpg?fit=crop&auto=format)
DESTINY-Breast03 and DESTINY-Breast06 Data Shape Metastatic Breast Cancer Treatment
During the 2024 ASCO Annual Meeting, investigators shared preliminary and updated findings from 2 phase 3 studies evaluating the HER2-directed antibody-drug conjugate (ADC) fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) against different comparators in …